Scott A Schobel1, Giuseppe Palermo2, Peggy Auinger2, Jeffrey D Long2, Shiyang Ma2, Omar S Khwaja2, Dylan Trundell2, Merit Cudkowicz2, Steven Hersch2, Cristina Sampaio2, E Ray Dorsey2, Blair R Leavitt2, Karl D Kieburtz2, Jeffrey J Sevigny2, Douglas R Langbehn2, Sarah J Tabrizi2. 1. From F. Hoffman-La Roche, Ltd (S.A.S., G.P., O.S.K., D.T., J.J.S.), Roche Innovation Center, Basel, Switzerland; University of Rochester (P.A., S.M., E.R.D., K.D.K.), NY; University of Iowa (J.D.L., D.R.L.), Iowa City; Massachusetts General Hospital and Harvard Medical School (M.C., S.H.), Boston; CHDI Management/Foundation (C.S.), Princeton, NJ; University of British Columbia, Vancouver, Canada (B.R.L.); and University College London (S.J.T.), UK. scott.schobel@roche.com. 2. From F. Hoffman-La Roche, Ltd (S.A.S., G.P., O.S.K., D.T., J.J.S.), Roche Innovation Center, Basel, Switzerland; University of Rochester (P.A., S.M., E.R.D., K.D.K.), NY; University of Iowa (J.D.L., D.R.L.), Iowa City; Massachusetts General Hospital and Harvard Medical School (M.C., S.H.), Boston; CHDI Management/Foundation (C.S.), Princeton, NJ; University of British Columbia, Vancouver, Canada (B.R.L.); and University College London (S.J.T.), UK.
Abstract
OBJECTIVE: To identify an improved measure of clinical progression in early Huntington disease (HD) using data from prospective observational cohort studies and placebo group data from randomized double-blind clinical trials. METHODS: We studied Unified Huntington Disease Rating Scale (UHDRS) and non-UHDRS clinical measures and brain measures of progressive atrophy in 1,668 individuals with early HD followed up prospectively for up to 30 to 36 months of longitudinal clinical follow-up. RESULTS: The results demonstrated that a composite measure of motor, cognitive, and global functional decline best characterized clinical progression and was most strongly associated with brain measures of progressive corticostriatal atrophy. CONCLUSIONS: Use of a composite motor, cognitive, and global functional clinical outcome measure in HD provides an improved measure of clinical progression more related to measures of progressive brain atrophy and provides an opportunity for enhanced clinical trial efficiency relative to currently used individual motor, cognitive, and functional outcome measures.
OBJECTIVE: To identify an improved measure of clinical progression in early Huntington disease (HD) using data from prospective observational cohort studies and placebo group data from randomized double-blind clinical trials. METHODS: We studied Unified Huntington Disease Rating Scale (UHDRS) and non-UHDRS clinical measures and brain measures of progressive atrophy in 1,668 individuals with early HD followed up prospectively for up to 30 to 36 months of longitudinal clinical follow-up. RESULTS: The results demonstrated that a composite measure of motor, cognitive, and global functional decline best characterized clinical progression and was most strongly associated with brain measures of progressive corticostriatal atrophy. CONCLUSIONS: Use of a composite motor, cognitive, and global functional clinical outcome measure in HD provides an improved measure of clinical progression more related to measures of progressive brain atrophy and provides an opportunity for enhanced clinical trial efficiency relative to currently used individual motor, cognitive, and functional outcome measures.
Authors: E Ray Dorsey; Christopher A Beck; Kristin Darwin; Paige Nichols; Alicia F D Brocht; Kevin M Biglan; Ira Shoulson Journal: JAMA Neurol Date: 2013-12 Impact factor: 18.302
Authors: B Kremer; C M Clark; E W Almqvist; L A Raymond; P Graf; C Jacova; M Mezei; M A Hardy; B Snow; W Martin; M R Hayden Journal: Neurology Date: 1999-09-22 Impact factor: 9.910
Authors: G Bernhard Landwehrmeyer; Bruno Dubois; Justo Garcia de Yébenes; Berry Kremer; Wilhelm Gaus; Peter H Kraus; Horst Przuntek; Michel Dib; Adam Doble; Wilhelm Fischer; Albert C Ludolph Journal: Ann Neurol Date: 2007-09 Impact factor: 10.422
Authors: Sarah J Tabrizi; Rachael I Scahill; Gail Owen; Alexandra Durr; Blair R Leavitt; Raymund A Roos; Beth Borowsky; Bernhard Landwehrmeyer; Chris Frost; Hans Johnson; David Craufurd; Ralf Reilmann; Julie C Stout; Douglas R Langbehn Journal: Lancet Neurol Date: 2013-05-09 Impact factor: 44.182
Authors: I Shoulson; C Odoroff; D Oakes; J Behr; D Goldblatt; E Caine; J Kennedy; C Miller; K Bamford; A Rubin Journal: Ann Neurol Date: 1989-03 Impact factor: 10.422
Authors: Andrew McGarry; Michael McDermott; Karl Kieburtz; Elisabeth A de Blieck; Flint Beal; Karen Marder; Christopher Ross; Ira Shoulson; Peter Gilbert; William M Mallonee; Mark Guttman; Joanne Wojcieszek; Rajeev Kumar; Mark S LeDoux; Mary Jenkins; H Diana Rosas; Martha Nance; Kevin Biglan; Peter Como; Richard M Dubinsky; Kathleen M Shannon; Padraig O'Suilleabhain; Kelvin Chou; Francis Walker; Wayne Martin; Vicki L Wheelock; Elizabeth McCusker; Joseph Jankovic; Carlos Singer; Juan Sanchez-Ramos; Burton Scott; Oksana Suchowersky; Stewart A Factor; Donald S Higgins; Eric Molho; Fredy Revilla; John N Caviness; Joseph H Friedman; Joel S Perlmutter; Andrew Feigin; Karen Anderson; Ramon Rodriguez; Nikolaus R McFarland; Russell L Margolis; Eric S Farbman; Lynn A Raymond; Valerie Suski; Sandra Kostyk; Amy Colcher; Lauren Seeberger; Eric Epping; Sherali Esmail; Nancy Diaz; Wai Lun Alan Fung; Alan Diamond; Samuel Frank; Philip Hanna; Neal Hermanowicz; Leon S Dure; Merit Cudkowicz Journal: Neurology Date: 2016-12-02 Impact factor: 9.910
Authors: Filipe B Rodrigues; Lauren M Byrne; Rosanna Tortelli; Eileanoir B Johnson; Peter A Wijeratne; Marzena Arridge; Enrico De Vita; Naghmeh Ghazaleh; Richard Houghton; Hannah Furby; Daniel C Alexander; Sarah J Tabrizi; Scott Schobel; Rachael I Scahill; Amanda Heslegrave; Henrik Zetterberg; Edward J Wild Journal: Sci Transl Med Date: 2020-12-16 Impact factor: 17.956
Authors: Naghmeh Ghazaleh; Richard Houghton; Giuseppe Palermo; Scott A Schobel; Peter A Wijeratne; Jeffrey D Long Journal: Front Neurol Date: 2021-05-20 Impact factor: 4.003